RXR alpha/PPAR gamma
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats RXR alpha/PPAR gamma as ChEMBL target CHEMBL2111394, mapped to UniProt P37231. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why RXR alpha/PPAR gamma matters
RXR alpha/PPAR gamma is reviewed as Peroxisome proliferator-activated receptor gamma (UniProt P37231); the current evidence base includes 3 approved drugs, 56 compounds, and 38 assays, with lead potency reaching pChEMBL 9.0.
Peroxisome proliferator-activated receptor gamma Sequence length is 505 aa.
Review this target as RXR alpha/PPAR gamma, mapped to UniProt P37231. ChEMBL maps the protein component as Peroxisome proliferator-activated receptor gamma. Sequence length is 505 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 3 approved drugs, 56 compounds, and 38 assays for this target. The dominant activity type is EC50. CHEMBL88740 is the current potency anchor at pChEMBL 9.0.
Use CHEMBL88740 as the tractability anchor when discussing potency (pChEMBL 9.0).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why RXR alpha/PPAR gamma matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P37231, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL88740
|
9.0 | EC50 | — |
|
|
No preferred name
CHEMBL92487
|
8.7 | EC50 | — |
|
|
No preferred name
CHEMBL92050
|
8.7 | EC50 | — |
|
|
No preferred name
CHEMBL325592
|
8.6 | EC50 | — |
|
|
No preferred name
CHEMBL42314
|
8.5 | EC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
BEXAROTENE
CHEMBL1023
|
1999 |
|
|
PIOGLITAZONE HYDROCHLORIDE
CHEMBL1715
|
1999 |
|
|
ROSIGLITAZONE MALEATE
CHEMBL843
|
1999 |